Build SBIR Biotech Commercialization Gap Database for Pharma BD Teams
- Organization
- NSF SBIR Phase I program's public award database (information asymmetry)
- Sector
- Pharma business development teams hunting for de-risked assets at fire-sale prices
- Location
- Location unspecified
Source reference
Executive summary
Current state
NSF awarded $305K SBIR Phase I grant to AICONIC BIOSCIENCES LLC for AI-assisted gene therapy platform targeting hearing disorders, creating an 18-month research validation period ending Dec 2027 with no automatic commercialization pathway. The structural discontinuity between academic validation and market deployment represents a $350M revenue opportunity trapped by institutional design constraints.
Market catalyst
NSF publishes SBIR award data but doesn't track what happens post-grant. Pharma BD teams need real-time intelligence on which technologies validate, which teams fail to secure follow-on funding, and which therapeutic areas have highest abandonment rates - creating a $50K+/year data product opportunity.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.